Picture of Arecor Therapeutics logo

AREC Arecor Therapeutics News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

REG - Arecor Therapeutics - ARECOR COMMENCES US PHASE I TRIAL OF AT247

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220120:nRST0217Za&default-theme=true

RNS Number : 0217Z  Arecor Therapeutics PLC  20 January 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN
COMBINATION WITH AN INSULIN PUMP

 

First patient dosed in potential game-changing diabetes combination therapy

 

Cambridge, UK, 20 January 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announces that it has commenced the US

Phase I clinical trial of Arecor's lead product, AT247, an ultra-rapid insulin
to be delivered by continuous subcutaneous infusion via insulin pump over a
period of three days.

 

The trial is a double blind, randomised, three-way crossover study comparing
the pharmacokinetics (PK) and pharmacodynamics (PD) of AT247 with Novo
Nordisk's NovoRapid® and Fiasp®, two market-leading rapid acting insulin
treatments in 24 participants with type I diabetes. It will be the first trial
to investigate the product's potential when delivered by continuous
subcutaneous infusion via insulin pump over a period of three days and follows
a previous successful first-in-man clinical study.

 

AT247, a novel proprietary formulation of insulin, aims to accelerate insulin
absorption, post injection, to enable more effective management of blood
glucose levels for people living with diabetes.  AT247 has the potential to
significantly improve post prandial glucose control so avoiding episodes of
both hypo and hyperglycemia.  In a European Phase I clinical study in Type I
diabetic patients published in 2021, AT247 exhibited an earlier insulin
appearance, exposure, and offset, with corresponding enhanced early
glucose-lowering effect compared with NovoRapid® and Fiasp®. This new trial
is targeted for completion in H2 2022 and is expected to provide additional
evidence that AT247 has the potential to facilitate a fully closed loop
artificial pancreas, a potentially life changing treatment option for people
living with diabetes.

 

Sarah Howell, Chief Executive Officer of Arecor, said:  "We are excited to be
initiating our first US clinical study that has been designed to further
demonstrate the superiority of AT247 compared to current best-in-class
insulins available to patients on the market today.  Understanding the
characteristics of AT247 when delivered via an infusion pump is important and
may facilitate a fully closed loop artificial pancreas, transforming the lives
of the c.537 million people living with diabetes."

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014 (MAR)

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray          Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBKCBQKBKBADD

Recent news on Arecor Therapeutics

See all news